Abstract
Angiotensin-converting enzyme (ACE) inhibitors reduce morbidity, mortality, hospital admissions, and decline in physical function and exercise capacity in congestive heart failure (CHF) patients. These therapeutic effects are attributed primarily to beneficial cardiovascular actions of these drugs. However, it has been suggested that ACE inhibitorinduced positive effects may also be mediated by direct action on the skeletal muscle. In particular, two recently published observational studies documented that among hypertensive subjects free of CHF, treatment with ACE inhibitors was associated with better performance and muscular outcomes and genetic studies also support the hypothesis that the ACE system may be involved in physical performance and skeletal muscle function. Effects on the skeletal muscle are probably mediated by mechanical, metabolic, anti-inflammatory, nutritional, neurological and angiogenetic actions of these drugs. These studies may have major public health implications for older adults, as consequence of the fact that, in this population, gradual loss of muscle mass and muscle strength can play a key role in the onset and progression of disability. Therefore, if findings of observational studies will be later confirmed in randomized controlled trials, ACE inhibitors could represent an effective intervention to prevent physical decline in the elderly, leading to greater autonomy in this growing population.
Keywords: ACE inhibitors, skeletal muscle, disability, sarcopenia, older adults
Current Pharmaceutical Design
Title: Effects of ACE Inhibitors on Skeletal Muscle
Volume: 12 Issue: 16
Author(s): Graziano Ondera, Cecilia D. Vedova and Marco Pahorc
Affiliation:
Keywords: ACE inhibitors, skeletal muscle, disability, sarcopenia, older adults
Abstract: Angiotensin-converting enzyme (ACE) inhibitors reduce morbidity, mortality, hospital admissions, and decline in physical function and exercise capacity in congestive heart failure (CHF) patients. These therapeutic effects are attributed primarily to beneficial cardiovascular actions of these drugs. However, it has been suggested that ACE inhibitorinduced positive effects may also be mediated by direct action on the skeletal muscle. In particular, two recently published observational studies documented that among hypertensive subjects free of CHF, treatment with ACE inhibitors was associated with better performance and muscular outcomes and genetic studies also support the hypothesis that the ACE system may be involved in physical performance and skeletal muscle function. Effects on the skeletal muscle are probably mediated by mechanical, metabolic, anti-inflammatory, nutritional, neurological and angiogenetic actions of these drugs. These studies may have major public health implications for older adults, as consequence of the fact that, in this population, gradual loss of muscle mass and muscle strength can play a key role in the onset and progression of disability. Therefore, if findings of observational studies will be later confirmed in randomized controlled trials, ACE inhibitors could represent an effective intervention to prevent physical decline in the elderly, leading to greater autonomy in this growing population.
Export Options
About this article
Cite this article as:
Ondera Graziano, Vedova D. Cecilia and Pahorc Marco, Effects of ACE Inhibitors on Skeletal Muscle, Current Pharmaceutical Design 2006; 12 (16) . https://dx.doi.org/10.2174/138161206777442137
DOI https://dx.doi.org/10.2174/138161206777442137 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
Food-derived bioactive peptides against chronic diseases
Chronic diseases, such as cardiovascular diseases and metabolic diseases, have become a great threat to the human health in recent decades due to the excessive food consumption and the prevalence of sedentary lifestyle. As a class of natural compounds, food-derived bioactive peptides have been demonstrated to possess great potential for ...read more
Innovative delivery systems and formulations for the management of diseases affecting the skin and skin appendages
Skin and skin appendage diseases have high incidence and can highly impact the quality of life. Such diseases include pigmentation disorders, such as melasma, vitiligo and post-inflammatory hyperpigmentation, infectious diseases caused by fungi, viruses, bacteria and parasites, inflammatory diseases such as acne, dermatitis, rosacea, and psoriasis, as well as skin ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Bioactive Coatings for Minimally Invasive Medical Devices: Surface Modification in the Service of Medicine
Recent Patents on Biomedical Engineering (Discontinued) Potential MicroRNA Targets for Cancer Chemotherapy
Current Medicinal Chemistry Streptozotocin-Induced Diabetes Mellitus in Neonatal Rats: An Insight into its Applications to Induce Diabetic Complications
Current Diabetes Reviews Future Therapeutic Directions: New Medications and Insulin Delivery in a Changing World for Effective Diabetes Management
Current Drug Discovery Technologies Sealing the Broken Barrier in IBD: Intestinal Permeability, Epithelial Cells and Junctions
Current Drug Targets Yeast as a Humanized Model Organism for Biotransformation-Related Toxicity
Current Drug Metabolism Reading and Writing the Blood-Brain Barrier: Relevance to Therapeutics
Recent Patents on CNS Drug Discovery (Discontinued) Beta Blocker Use After Acute Myocardial Infarction in the Patient with Normal Systolic Function: When is it “Ok” to Discontinue?
Current Cardiology Reviews C-11 Radiochemistry in Cancer Imaging Applications
Current Topics in Medicinal Chemistry Targeting the Platelet Integrin GPIIb/IIIa
Current Pharmaceutical Design Alcoholic/Nonalcoholic Fatty Liver Disease Detection with Transient Elastography: A Detailed Review and Meta-analysis
Current Medical Imaging Intestinal Transport as a Potential Determinant of Drug Bioavailability
Current Clinical Pharmacology COX-2: Friend or Foe?
Current Pharmaceutical Design Connexins in Renal Endothelial Function and Dysfunction
Cardiovascular & Hematological Disorders-Drug Targets Exosome-like Nanoparticles: A New Type of Nanocarrier
Current Medicinal Chemistry Difficult/Therapy-Resistant Asthma: Pathogenesis and Possible Relationship with Tobacco Smoke
Current Respiratory Medicine Reviews Adolescents’ Rights: Better for Promoting Individual Rights or Public Health?
Adolescent Psychiatry Aligning Animal Models of Clinical Germinal Matrix Hemorrhage, From Basic Correlation to Therapeutic Approach
Current Drug Targets Exploring the High Burden of Cardiovascular Disease Among Patients with End-Stage Renal Disease
Current Vascular Pharmacology Novel uses of Imaging in AF Ablation
Recent Patents on Cardiovascular Drug Discovery